• Explore /
  • Poster
  • / Comparing the efficacy of abiraterone and enzalutamide in United States veterans with metastatic castration-sensitive prostate cancer (mCSPC) by estimating rates of tumor growth (<em>g</em>-rate).

Comparing the efficacy of abiraterone and enzalutamide in United States veterans with metastatic castration-sensitive prostate cancer (mCSPC) by estimating rates of tumor growth (g-rate).

Abstract Poster

Authors

null

Harshraj Leuva

University of Nebraska Medical Center, Omaha, NE

Harshraj Leuva , Mengxi Zhou , Rumen Stamatov , Benjamin A. Teply , Ta-Chueh Melody Rosenberg , Carol A. Luhrs , Prabhjot Singh Mundi , Yeun-Hee Anna Park , Susan Elaine Bates , Izak Faiena , Antonio Tito Fojo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Hormone-Sensitive

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5076)

DOI

10.1200/JCO.2023.41.16_suppl.5076

Abstract #

5076

Poster Bd #

170

Abstract Disclosures

Funded by Conquer Cancer

Similar Posters

First Author: Harshraj Leuva

Poster

2022 ASCO Genitourinary Cancers Symposium

Predictive factors for effectiveness from novel androgen-receptor-axis-targeted agents in patients with metastatic prostate cancer.

Predictive factors for effectiveness from novel androgen-receptor-axis-targeted agents in patients with metastatic prostate cancer.

First Author: Koshiro Nishimoto

First Author: Lin Wang

First Author: Akiyuki Yamamoto